Novartis (NYSE: NVS) announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studiesMay 20, 2015 11:45 AM Maverick Capital Boosts Google (GOOG) Stake, Exits Alibaba (BABA), Qihoo (QIHU) - 13FMay 18, 2015 6:12 AM